Paysign Q4 2025 revenue rose 45.8% to USD 23 million as adjusted EBITDA climbed 89.6% to USD 5 million

Reuters03-25

Paysign Q4 2025 revenue rose 45.8% to USD 23 million as adjusted EBITDA climbed 89.6% to USD 5 million

Paysign published a quarterly and annual earnings press release reporting Q4 revenue of USD 22.76 million, up 45.8%.
Q4 net income was USD 1.36 million and adjusted EBITDA was USD 5.43 million, up 89.6%.
FY revenue was USD 82.03 million, up 40.5%, driven by a 4% increase in plasma revenue to USD 45.62 million and more than doubled pharma revenue to USD 33.89 million on 55 net patient affordability programs added.
FY net income was USD 7.55 million, up 97.9%, while adjusted EBITDA was USD 19.94 million, up 107.3%.
Management forecast FY 2026 revenue of USD 106.5 million to USD 110.5 million and net income of USD 13 million to USD 16 million, and said plasma revenue is expected to be lowest in Q1 due to reduced donor frequency after tax refunds while pharma revenue is expected to be highest in Q1 and decline as claims ramp down.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Paysign Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603241610BIZWIRE_USPR_____20260324_BW307491) on March 24, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622018015?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 04:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622018015","market":"nz","top_or_hot":-1,"title":"Paysign Q4 2025 revenue rose 45.8% to USD 23 million as adjusted EBITDA climbed 89.6% to USD 5 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Paysign Q4 2025 revenue rose 45.8% to USD 23 million as adjusted EBITDA climbed 89.6% to USD 5 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Paysign published a quarterly and annual earnings press release reporting Q4 revenue of USD 22.76 million, up 45.8%.\n        </li>\n<li>\n          Q4 net income was USD 1.36 million and adjusted EBITDA was USD 5.43 million, up 89.6%.\n        </li>\n<li>\n          FY revenue was USD 82.03 million, up 40.5%, driven by a 4% increase in plasma revenue to USD 45.62 million and more than doubled pharma revenue to USD 33.89 million on 55 net patient affordability programs added.\n        </li>\n<li>\n          FY net income was USD 7.55 million, up 97.9%, while adjusted EBITDA was USD 19.94 million, up 107.3%.\n        </li>\n<li>\n          Management forecast FY 2026 revenue of USD 106.5 million to USD 110.5 million and net income of USD 13 million to USD 16 million, and said plasma revenue is expected to be lowest in Q1 due to reduced donor frequency after tax refunds while pharma revenue is expected to be highest in Q1 and decline as claims ramp down.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/PAYS\">Paysign Inc</a>. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603241610BIZWIRE_USPR_____20260324_BW307491) on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Paysign Q4 2025 revenue rose 45.8% to USD 23 million as adjusted EBITDA climbed 89.6% to USD 5 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPaysign Q4 2025 revenue rose 45.8% to USD 23 million as adjusted EBITDA climbed 89.6% to USD 5 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-25 04:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Paysign Q4 2025 revenue rose 45.8% to USD 23 million as adjusted EBITDA climbed 89.6% to USD 5 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Paysign published a quarterly and annual earnings press release reporting Q4 revenue of USD 22.76 million, up 45.8%.\n        </li>\n<li>\n          Q4 net income was USD 1.36 million and adjusted EBITDA was USD 5.43 million, up 89.6%.\n        </li>\n<li>\n          FY revenue was USD 82.03 million, up 40.5%, driven by a 4% increase in plasma revenue to USD 45.62 million and more than doubled pharma revenue to USD 33.89 million on 55 net patient affordability programs added.\n        </li>\n<li>\n          FY net income was USD 7.55 million, up 97.9%, while adjusted EBITDA was USD 19.94 million, up 107.3%.\n        </li>\n<li>\n          Management forecast FY 2026 revenue of USD 106.5 million to USD 110.5 million and net income of USD 13 million to USD 16 million, and said plasma revenue is expected to be lowest in Q1 due to reduced donor frequency after tax refunds while pharma revenue is expected to be highest in Q1 and decline as claims ramp down.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/PAYS\">Paysign Inc</a>. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603241610BIZWIRE_USPR_____20260324_BW307491) on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4227","symbol_name":"交易和支付处理服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL6Gh4DB:1","article_id":"2622018015","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622018015","pubTimestamp":1774383025,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Paysign published a quarterly and annual earnings press release reporting Q4 revenue of USD 22.76 million, up 45.8%.Q4 net income was USD 1.36 million and adjusted EBITDA was USD 5.43 million, up 89.6%.FY revenue was USD 82.03 million, up 40.5%, driven by a 4% increase in plasma revenue to USD 45.62 million and more than doubled pharma revenue to USD 33.89 million on 55 net patient affordability programs added.FY net income was USD 7.55 million, up 97.9%, while adjusted EBITDA was USD 19.94 million, up 107.3%.Management forecast FY 2026 revenue of USD 106.5 million to USD 110.5 million and net income of USD 13 million to USD 16 million, and said plasma revenue is expected to be lowest in Q1 due to reduced donor frequency after tax refunds while pharma revenue is expected to be highest in Q1 and decline as claims ramp down.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4227":"交易和支付处理服务","PAYS":"Paysign Inc","BK4106":"数据处理与外包服务"},"translate_title":"Paysign 2025年第四季度收入增长45.8%至2300万美元，调整后EBITDA增长89.6%至500万美元","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PAYS":0.9},"content_text":"Paysign Q4 2025 revenue rose 45.8% to USD 23 million as adjusted EBITDA climbed 89.6% to USD 5 million\n    \n\n\n          Paysign published a quarterly and annual earnings press release reporting Q4 revenue of USD 22.76 million, up 45.8%.\n        \n\n          Q4 net income was USD 1.36 million and adjusted EBITDA was USD 5.43 million, up 89.6%.\n        \n\n          FY revenue was USD 82.03 million, up 40.5%, driven by a 4% increase in plasma revenue to USD 45.62 million and more than doubled pharma revenue to USD 33.89 million on 55 net patient affordability programs added.\n        \n\n          FY net income was USD 7.55 million, up 97.9%, while adjusted EBITDA was USD 19.94 million, up 107.3%.\n        \n\n          Management forecast FY 2026 revenue of USD 106.5 million to USD 110.5 million and net income of USD 13 million to USD 16 million, and said plasma revenue is expected to be lowest in Q1 due to reduced donor frequency after tax refunds while pharma revenue is expected to be highest in Q1 and decline as claims ramp down.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Paysign Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603241610BIZWIRE_USPR_____20260324_BW307491) on March 24, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622018015","isCrawlerRequest":true}